Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027

Vir Biotechnology, Inc.

2025-Q1 EPS reported -$0.88 revenue$3,032,000

Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.
Initiated Phase 3 ECLIPSE registrational program for chronic hepatitis delta; first patient enrolled March 2025.
Cash and investments ~$1.02B, down $75.6M in Q1; cash runway into mid-2027.
Alnylam opted out of profit-sharing for elebsiran in CHB/CHD; Vir seeking partner for CHB development.
Dose escalation ongoing for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA); Phase 1 for VIR-5525 (EGFR) planned Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.